Participants may not have any evidence of ongoing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg); patients with hypertension may not be on more than three antihypertensive medications for management of their blood pressure (medications that combine two anti-hypertensives into one are considered as two medications); it is strongly recommended that patients who require three antihypertensive medications for baseline management of pre-existing hypertension be actively followed by a cardiologist or blood pressure specialist for management of BP while on protocolXx_NEWLINE_xXAdequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; a cardiologist or blood pressure specialist must evaluate patients who are on 3 antihypertensive medications within 4 weeks of enrollmentXx_NEWLINE_xXUncontrolled hypertension defined as systolic > 150 or diastolic > 100 mm Hg on the average of the 3 most recent BP readings. Anti-hypertensives may be started prior to randomization.Xx_NEWLINE_xXUncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)Xx_NEWLINE_xXUncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP 90 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteriaXx_NEWLINE_xXDiastolic BP =< 90 mg HGXx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height, and gender for pediatric patients < 18 years old and =< 140/90 mmHg for patients >= 18 years old; patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP =< ULN for pediatric patients and =< 140/90 for adult patients); please note that 3 serial blood pressures should be obtained and averaged to determine baseline BPXx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1Xx_NEWLINE_xXUncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); Note: patients may be rescreened after adjustment of antihypertensive medicationsXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXA blood pressure (BP) =< 95% percentile for age, height, and gender; patients on stable doses of no more than one anti-hypertensive medication, with a baseline BP =< 95% percentile for age, height, and gender will be eligibleXx_NEWLINE_xXHistory of uncontrolled hypertension (Blood pressure ? _140/90 mmHg and change in antihypertensive medication within 7 days prior to randomization) that is not well managed by medication and the risk of which may be precipitated by a VEGF inhibitor therapy.Xx_NEWLINE_xXUncontrolled high blood pressure defined as systolic blood pressure (BP) greater than or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.Xx_NEWLINE_xXUncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg.Xx_NEWLINE_xXUncontrolled or poorly controlled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg); Note: an isolated reading that is not sustained will be permittedXx_NEWLINE_xXParticipants with a history of hypertension must be adequately controlled with antihypertensive medication and blood pressure (BP) must be less than 140/90 mmHg prior to initiation of ziv-afliberceptXx_NEWLINE_xXUncontrolled hypertension defined as sustained systolic BP > 150 mmHg or diastolic BP > 90 mmHg. (Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.) Patients requiring greater than or equal to 3 BP medications are not eligible.Xx_NEWLINE_xXSystolic blood pressure (BP) not deemed clinically controlled by the investigator.Xx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 millimeters of mercury (mmHg) at Screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1Xx_NEWLINE_xXAdequate Blood Pressure Control defined as a blood pressure (BP) <= the 95th percentile for age, height, and gender measured, subjects on stable doses of no more than one anti-hypertensive medication, with a baseline BP <= 95th percentile for age, height and gender, will be eligible.Xx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height, and gender, and not receiving medication for treatment of hypertension; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BPXx_NEWLINE_xXNo grade 3 or 4 hypertension (systolic blood pressure [BP] > 160 and or diastolic BP > 100) that cannot be controlled with medication prior to registrationXx_NEWLINE_xXParticipant with an uncontrolled intercurrent illness including, but not limited to;\r\n* Ongoing or active infection, \r\n* Symptomatic congestive heart failure, \r\n* Unstable angina pectoris, \r\n* Cardiac arrhythmia, \r\n* A persistent grade 3 hypertension (as defined as stage 2 hypertension with systolic blood pressure [BP] >= 160 mm Hg or diastolic BP >= 100 mm Hg and medical intervention indicated) based on the baseline and previous BP readings if available\r\n* Psychiatric illness/social situations that will limit compliance with study requirementsXx_NEWLINE_xXInadequately controlled hypertension (ie, systolic blood pressure [SBP] >160 mmHg or diastolic BP [DBP] >90 mmHg) at 2 separate measurements no more than 60 minutes apart during the Screening visit. Note: patients may be rescreened after adjustment of antihypertensive medications.Xx_NEWLINE_xXUncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; orXx_NEWLINE_xXHistory of any of the following cardio-vascular condition:\r\n* Myocardial infarction (MI)\r\n* Unstable angina\r\n* Coronary artery bypass grafting (CABG)\r\n* Coronary angioplasty or stenting\r\n* Symptomatic peripheral arterial disease (PAD)\r\n* History of symptomatic chronic congestive heart failure (CHF)\r\n* History of cerebrovascular accidents including transient ischemic attacks (TIA)\r\n* Corrected QT interval (QTc) > 480 msec\r\n* Uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic BP of > 90 mm Hg); if the screening BP is elevated, adjustments in anti-hypertensives are permitted and a re-screening will be permitted for BP assessment with three consecutive values obtained 2 minutes apart; the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication; use of clonidine is not permissible for adjusting the BP during this periodXx_NEWLINE_xXUncontrolled hypertension (blood pressure [BP] > 150/100 mmHg)Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg)Xx_NEWLINE_xXNo evidence of uncontrolled hypertension as documented by 2 baseline blood pressure (BP) readings taken at least 1 hour apart; the baseline systolic BP readings must be =< 140 mm Hg, and the baseline diastolic BP readings must be =< 90 mm Hg; use of antihypertensive medications to control BP is allowedXx_NEWLINE_xXSignificant medical condition other than cancer, that would prevent consistent and compliant participation in the study that would, in the opinion of the investigator, make this protocol unreasonably hazardous including but not limited to:\r\n* Any medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone once daily\r\n* History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents\r\n* Uncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment (systolic BP <160 mmHg or diastolic BP <95 mmHg)\r\n* Active or symptomatic viral hepatitis or chronic liver disease\r\n* Known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection. (HIV testing is not mandatory)\r\n* History of pituitary or adrenal dysfunction\r\n* Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) class III or IV heart disease or cardiac ejection fraction measurement of < 50% at baseline, or clinically significant ventricular arrhythmias within 6 months prior to treatment start.\r\n* History of seizure or any condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness =< 1 year prior to treatment start; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)\r\n* Uncontrolled diabetes mellitus\r\n* History of inflammatory bowel disease\r\n* Baseline moderate and severe hepatic impairment (Child Pugh class B & C)Xx_NEWLINE_xXAdequately controlled blood pressure with or without antihypertensive medications defined as blood pressure (BP) < 140/90 mmHg at screening and no change in antihypertensive mediation within 1 week prior to the screening visitXx_NEWLINE_xXUncontrolled hypertension. Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy. Note that this is NOT a criterion related to particular blood pressure (BP) results at the time of assessment for eligibility, nor does it apply to acute BP excursions that are related to iatrogenic causes, acute pain or other transient, reversible causesXx_NEWLINE_xXAdequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of BP while on protocolXx_NEWLINE_xXChronically uncontrolled hypertension, defined conventionally as consistent systolic pressures above 170 or diastolic pressures above 110 despite anti-hypertensive therapy. Note that this is NOT a criterion related to particular blood pressure (BP) results at the time of assessment for eligibility, nor does it apply to acute BP excursions that are related to iatrogenic causes, acute pain or other transient, reversible causes. (for example doctor’s visit related stress i.e. \white coat syndrome\.Xx_NEWLINE_xXUncontrolled cardiac disease, including unstable angina, uncontrolled hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), or need to change medication due to lack of disease control within 6 weeks prior to the provision of consent;Xx_NEWLINE_xXHypertension defined as blood pressure (BP) systolic > 150 or diastolic > 90 mm Hg (Note: Initiation or adjustment of antihypertensive medication prior to study entry is allowed provided that the average of 3 BP readings prior to study treatment is ?150/90 mm Hg.)Xx_NEWLINE_xXUncontrolled hypertension defined as a systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg, with or without anti-hypertensive medicationsXx_NEWLINE_xXNo clinically significant cardiovascular disease including:\r\n* Myocardial infarction (MI) within 6 months\r\n* Uncontrolled angina within 3 months\r\n* Chronic heart failure (CHF) with New York Heart Association (NYHA) class 3 or 4, or patients with NYHA class 3 or 4 in the past, unless a screening echo or multigated acquisition scan (MUGA) performed within three months demonstrates an ejection fraction (EF) > 45% \r\n* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, Torsades de pointes)\r\n* History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place\r\n* Hypotension (systolic blood pressure [BP] < 86 mmHg) or bradycardia (< 50 beat per minute [bpm]) at screening\r\n* Uncontrolled hypertension (systolic BP >170 mmHg or diastolic BP >105 mmHg at screening)Xx_NEWLINE_xXBlood pressure (BP) =< 95th percentile for age, height, and gender and not receiving medication for treatment of hypertensionXx_NEWLINE_xXPatients with significant cardiac history including:\r\n* Severe or unstable angina pectoris\r\n* Uncontrolled hypertension (defined as systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg;. Note - patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment\r\n* Atrial fibrillation or other cardiac arrhythmia requiring therapy.\r\n* Heart disease as evidenced by myocardial infarction, or aterial thrombotic events in the past 6 months\r\n* Class II-IV heart failure (as defined by New York Heart Association) or a cardiac ejection fraction measurement of less than 50% at baselineXx_NEWLINE_xXAdequately controlled blood pressure (BP) < 140 mmHg (systolic) and < 90 mmHg (diastolic) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of 3 antihypertensive medications; patients who are on 3 antihypertensive medications are highly recommended to be followed by a cardiologist or blood pressure specialist for management of BP while on protocolXx_NEWLINE_xXUncontrolled hypertension (HTN); sustained blood pressure (BP) greater than 150/100 mmHgXx_NEWLINE_xXBlood pressure (BP) < 150 mmHg (systolic) and < 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 150/90 mmHg; NOTE: all patients with secretory pheochromocytoma or paraganglioma are REQUIRED to: 1) be evaluated in consultation by a hypertension specialist with specific experience in the management of hypertension in the setting of catecholamine-secreting tumors (usually an endocrinologist, nephrologist, or a cardiologist), and in the setting of hormone-associated hypertension) receive alpha- and beta-adrenergic blockade for at least 7-14 days prior to initiation of lenvatinib; the hypertension specialist of record for each patient should be committed to closely following the patient during the clinical study with evaluation by said specialist required at cycle 1 and 2 and thereafter on an as needed basisXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg) or other medical condition that could jeopardize the assessment of toxicity on studyXx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height and gender despite optimal antihypertensive treatment within 7 days of the first dose of the study treatment; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BPXx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height, and gender and not receiving medication for treatment of hypertensionXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 140 mmHg or diastolic BP >= 90 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXSystolic blood pressure (BP) > 160 mmHg or diastolic BP > 100 mmHg despite optimal medical managementXx_NEWLINE_xXUncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose and meet all other inclusion criteria; orXx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height, and gender measured within 7 days prior to enrollment; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP; patients with hypertension controlled on antihypertensive medications will be allowed if otherwise eligibleXx_NEWLINE_xXResting systolic blood pressure (BP) < 100 mmHgXx_NEWLINE_xXHypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical managementXx_NEWLINE_xXPatients must have adequately controlled blood pressure (BP), with a BP no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocolXx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as: BP less than 95th percentile for sex, age, and height/length at screening (as per National Heart Lung and Blood Institute guidelines) and no change in antihypertensive medications within 1-week prior to Cycle 1/Day 1. Osteosarcoma subjects 18 to 25 years should have BP ?150/90 mm Hg at screening and no change in antihypertensive therapy within 1 week prior to Cycle 1/Day 1.Xx_NEWLINE_xXUncontrolled chronic hypertension defined as systolic > 150 or diastolic > 90 despite optimal therapy (initiation or adjustment of blood pressure (BP) medication prior to study entry is allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg)Xx_NEWLINE_xXPatients must have controlled blood pressure with a systolic blood pressure < 140 mmHg and diastolic < 90 mmHg (for patients with an elevated initial blood pressure (BP) reading [hypertensive range], a repeat measurement at least 2 minutes later should be performed, and the two readings should be averaged to obtain a BP reading); any hypertensive at-home blood pressure reading will be confirmed in clinic; patients on anti-hypertensive medications are eligible, if blood pressure is controlled; study drug dosing will be interrupted for any reading >= 160/100Xx_NEWLINE_xXUncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic BP greater than 90 mmHg, with or without anti-hypertensive medications. (Patients with hypertension that is well controlled on medication are eligible.)Xx_NEWLINE_xXThe subject has serious intercurrent illness as determined by the treating physician, that would compromise either patient safety or study outcomes such as:\r\n* Hypertension (two or more blood pressure [BP] readings performed at screening of > 150 mmHg systolic or > 100 mmHg diastolic) despite optimal treatment\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Clinically significant cardiac arrhythmias\r\n* Untreated hypothyroidism\r\n* Uncontrolled systemic infection\r\n* Symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug\r\n* Myocardial infarction, stroke, transient ischemic attack within 6 months\r\n* Known active malignancy (other than their glioma) except non-melanoma skin cancer or carcinoma in-situ in the cervixXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP/DBP ratio must be < 140/90 mmHgXx_NEWLINE_xXSevere hypertension (diastolic BP > 100 on medication).Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 140 mmHg or diastolic BP >= 90 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXUncontrolled high blood pressure defined as systolic BP greater than or equal to 150 mmHg or diastolic BP greater than or equal to 100 mmHg with or without anti-hypertensive medication. Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.Xx_NEWLINE_xXuncontrolled hypertension (systolic BP> 180 mmHg or diastolic BP > 100 mmHg despite antihypertensive treatment);Xx_NEWLINE_xXSevere hypertension (diastolic BP > 100 on medication)Xx_NEWLINE_xXUncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)Xx_NEWLINE_xXPatients with uncontrolled hypertension (requirement for more than 2 blood pressure [BP] medications or grade 2 or higher BP elevation while on adequate doses of not more than 2 antihypertensive agents) are excluded from the studyXx_NEWLINE_xXMean arterial blood pressure (BP) of less than 70 mmHgXx_NEWLINE_xXNo history of the following\r\n* Prior brain metastases\r\n* Leptomeningeal disease\r\n* Seizures\r\n* Class 3 or 4 congestive heart failure\r\n* Uncontrolled hypertension (systolic blood pressure [BP] > 170 mmHg or diastolic BP > 105 mmHg) despite optimal medical management\r\n* Major surgery =< 4 weeks of registrationXx_NEWLINE_xXHave uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or diastolic BP > 100 mmHg).Xx_NEWLINE_xXPatients with BP combination treatment with more than two antihypertensive medications are ineligibleXx_NEWLINE_xXResting systolic blood pressure (BP) < 100 mmHgXx_NEWLINE_xXHypertension defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg despite optimal medical managementXx_NEWLINE_xXNo evidence of pre-existing uncontrolled hypertension as documented by 2 baseline blood pressure (BP) readings taken at least 1 hour apart; the baseline systolic BP readings must be =< 150 mm Hg, and the baseline diastolic BP readings must be =< 90 mm HgXx_NEWLINE_xXAdequately controlled blood pressure; (defined as systolic blood pressure [SBP] of < 140 mmHg and diastolic blood pressure [DBP] of < 90 mmHg) on maximum of three antihypertensive medications; participants must have a blood pressure (BP) of < 140/90 taken in the clinic or hospital setting by a medical professional within 2 weeks prior to starting on study; it is strongly recommended that participants who are on 3 antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on studyXx_NEWLINE_xXAdequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications must be actively followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib armsXx_NEWLINE_xXPoorly-controlled hypertension as defined blood pressure (BP) > 150/100 mmHg, or systolic (S) BP > 180 mmHg when diastolic (D) BP < 90 mmHg, on at least 2 repeated determinations on separate days within 3 months prior to study enrollmentXx_NEWLINE_xXUncontrolled hypertension (HTN) despite medical management (blood pressure [BP] >= 160/100)Xx_NEWLINE_xXCardiac conditions as follows:\r\n* Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 12 months prior to first study drug administration\r\n* Class II-IV New York Heart Association (NYHA) congestive heart failure\r\n* Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management; blood pressure must be below 140/90 mmHg at screening; subjects with a history of hypertension who are receiving treatment with calcium channel blockers that are cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) substrates should be changed to an alternative antihypertensive medication prior to first study drug administration\r\n* Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin\r\n* Corrected QT (QTc) (Frederica) prolongation > 480 msec\r\n* Subjects with valvular heart disease Common Terminology Criteria for Adverse Events (CTCAE) (version 4.0) grade 2\r\n* Known left ventricular ejection fraction (LVEF) < 50%Xx_NEWLINE_xXA blood pressure (BP) =< the 95th percentile for age, height, and gender measured, and not receiving medication for treatment of hypertension; please note that 3 serial blood pressures should be obtained and averaged to determine baseline BPXx_NEWLINE_xXUncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg; (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria)Xx_NEWLINE_xXBlood pressure (BP) > 140 mmHg (systolic) and > 90 mmHg (diastolic); initiation or adjustment of BP medication is permitted prior to registration provided that the average of three BP readings at a visit prior to registration is < 140/90 mmHgXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] greater than [>] 150 millimeters of mercury [mmHg] and/or diastolic BP > 100 mmHg), unstable angina, congestive heart failure of any New York Heart Association classification, serious cardiac arrhythmia that requires treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia, and history of myocardial infarction within 6 months of enrollmentXx_NEWLINE_xXUncontrolled chronic hypertension defined as systolic > 150 or diastolic > 90 despite optimal therapy (initiation or adjustment of BP medication prior to study entry is allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 150/90 mm Hg)Xx_NEWLINE_xXBlood pressure (BP) ? 140/90 millimeter of mercury (mmHg) at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapyXx_NEWLINE_xXSystolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg.Xx_NEWLINE_xXUncontrolled chronic hypertension defined as systolic > 150 or diastolic > 90 despite optimal therapy (initiation or adjustment of BP medication prior to study entry is allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 150/90 mm Hg)Xx_NEWLINE_xXuncontrolled hypertension (systolic BP ? 139 mmHg or diastolic BP ? 89 mmHg) at screening, despite optimal antihypertensive therapy,Xx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than or equal to 150/90 mmHg at screening and no change in antihypertensive medications within 1 week prior to the Cycle 1 Day 1.Xx_NEWLINE_xXPatients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as so judged by the treating physician; examples include but are not limited to:\r\n* Severely impaired lung function (e.g. use of home O2, history of idiopathic lung disease [ILD], any evidence of ILD on scan)\r\n* Active (acute or chronic) severe infections requiring treatment with I.V. antibiotics\r\n* Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis\r\n* Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); NOTE: initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry; following anti-hypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP/DBP ratio must be < 140/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXAdequately controlled blood pressure (BP) with up to 3 antihypertensive agents, defined as BP less than or equal to 150/90 mm Hg at Screening and no change in antihypertensive therapy within 1 week prior to the Cycle1/Day1Xx_NEWLINE_xXSevere hypertension (diastolic BP > 100 on medication)Xx_NEWLINE_xXParticipants may not have any evidence of ongoing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg); patients with hypertension may not be on more than three antihypertensive medications for management of their blood pressure (medications that combine two anti-hypertensives into one are considered as two medications); it is strongly recommended that patients who require three antihypertensive medications for baseline management of pre-existing hypertension be actively followed by a cardiologist or blood pressure specialist for management of BP while on protocolXx_NEWLINE_xXUncontrolled hypertension, i.e., blood pressure (BP) of >= 170/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteriaXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg)\r\nNote: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP / DBP ratio must be < 140/90 mmHg (or 150/90 mm Hg, if approved by principal investigator [PI] and the quality assurance monitor [QAM]) in order for a patient to be eligible for the studyXx_NEWLINE_xXBlood pressure < 150/90 at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to initiation of treatmentXx_NEWLINE_xXAdequate blood pressure (BP) control with or without antihypertensive medicationsXx_NEWLINE_xXNo clinically significant cardiovascular disease including:\r\n* Myocardial infarction (MI) within 6 months\r\n* Uncontrolled angina within 3 months\r\n* Congestive heart failure (CHF) with New York Heart Association (NYHA) class 3 or 4, or patients with NYHA class 3 or 4 in the past, unless a screening echocardiogram (echo) or multi gated acquisition scan (MUGA) performed within three months demonstrates an ejection fraction (EF) > 45%\r\n* History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)\r\n* History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place\r\n* Hypotension (systolic blood pressure [BP] < 86 mmHg) or bradycardia (< 50 beats per minute [bpm]) at screening \r\n* Uncontrolled hypertension (systolic BP > 170 mmHg or diastolic BP > 105 mmHg at screening)Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXHistory of any one or more of the following cardiovascular conditions within the past 6 months: \r\n* Cardiac angioplasty or stenting \r\n* Myocardial infarction \r\n* Unstable angina \r\n* Coronary artery bypass graft surgery \r\n* Symptomatic peripheral vascular disease\r\n* Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA)\r\n* Poorly controlled hypertension (defined as systolic blood pressure [SBP] of >=140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be =< 140/90 mmHg in order for a subject to be eligible for the study\r\n* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; Note: subjects with recent DVT who have been treated with therapeutic anticoagulating agents for at least 6 weeks are eligibleXx_NEWLINE_xXSubjects with uncontrolled hypertension (systolic blood pressure [BP] >180 mmHg or diastolic BP >100 mmHg) at screening are excluded. Subjects requiring 2 or more medications to control hypertension are eligible with Medical Monitor approval.Xx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP less than 150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1/Day 1 (C1D1).Xx_NEWLINE_xXPatients cannot have baseline hypotension, defined as systolic BP lower than 100 mm Hg on two readings obtained on two separate days prior to study enrollmentXx_NEWLINE_xXPatients with a history of hypertension MUST have hypertension adequately controlled (blood pressure [BP] < 140/90) with appropriate anti-hypertensive therapy or diet prior to study entry; Note: To be eligible a subject must have an average of BP below 140/90 based on 3 separate measures; if the subject has a record of BP recordings taken at home, =< 20% of BPs taken should have numbers > 140/90Xx_NEWLINE_xXPatients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at a visit prior to enrollment is less than 140/90 mmHgXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 150 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 150/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXBlood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings on baseline assessment prior to enrollment is less than 140/90 mmHgXx_NEWLINE_xXPoorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90 mmHg); Note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXUncontrolled hypertension defined as systolic blood pressure (BP) >= 140 mmHg or diastolic BP >= 90 mmHg with or without antihypertensive medication, based on a mean of 3 measurements at approximately 2-minute intervalsXx_NEWLINE_xXHypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg OR diastolic blood pressure [DBP] of >= 90 mmHg) in spite of optimal medical management; note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; in this event, blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP/DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the studyXx_NEWLINE_xXSignificant co-morbidity that could affect the safety or evaluability of participants, specifically including: \r\n* Chronically uncontrolled hypertension, defined conventionally as consistent systolic pressures above 140 or diastolic pressures above 90 despite therapy; note that this may be better established with home blood pressure (BP) readings than with clinic visit results; note further that this is NOT a criterion related to particular BP results at the time of assessment for eligibility, nor does it apply to acute BP excursions that are related to iatrogenic causes, acute pain or other transient, reversible causes; the intent is to exclude patients that may have unrecognized renal damage from chronic, uncontrolled hypertension, NOT to exclude patients who may be hypertensive acutely; there are no absolute criteria for BP readings with respect to eligibility (as determined by treating physician)\r\n* Uncontrolled diabetes mellitus, defined as: hemoglobin (Hgb) A1c > 8.5%; or symptomatic hypoglycemic episodes > 1 per week during the two months prior to eligibility evaluation; or more than 1 glucose excursion to > 300 mg/dL in prior two months--unless clearly iatrogenic and the cause has been eliminated \r\n* Lung disease requiring supplemental oxygen \r\n* Known chronic liver disease causing either fibrosis or synthetic dysfunction \r\n* Known human immunodeficiency virus (HIV) infection \r\n* Overt psychosis, mental disability or being otherwise incompetent to grant informed consent or a history of non-compliance with medical careXx_NEWLINE_xXUncontrolled hypertension (BP ?150/95 mmHg despite medical therapy)Xx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1 (C1/D1)Xx_NEWLINE_xXPatients may not have any evidence of pre-existing inadequately controlled hypertension (defined as a systolic blood pressure [BP] of > 140 mmHg or a diastolic BP of > 90 mmHg), and must have a normal blood pressure (=< 140/90 mmHg) taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; patients who are on three antihypertensive medications must be actively followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocolXx_NEWLINE_xXUncontrolled hypertension (blood pressure [BP] > 100 diastolic despite treatment with maximum doses of at least 3 simultaneous or concurrent antihypertensives over a 2-month period)Xx_NEWLINE_xXPatients who have persistently elevated systolic blood pressures (BPs) >= 145 or diastolic BPs >= 90 need to have their systolic or diastolic BP controlled with anti-hypertensive agents for at least 3 days prior to the initiation of cell therapy; patients already on anti-hypertensive agents will have their medicine adjusted based on the clinical judgment of the patient care teamXx_NEWLINE_xXSevere hypertension (diastolic blood pressure [BP] > 100 on medication)Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] ? 160 millimeters of mercury [mmHg] or diastolic BP ? 95 mmHg).Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXMean arterial blood pressure (BP) of less than 70 mmHg.Xx_NEWLINE_xXInadequately controlled hypertension defined as BP > 150/100 mm Hg despite medicationXx_NEWLINE_xXPatients must have resting blood pressure (BP) no greater than 140 mmHg (systolic) or 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entryXx_NEWLINE_xXUncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteriaXx_NEWLINE_xXUncontrolled hypertension despite appropriate medical therapy (blood pressure [BP] of greater than 160 mmHg systolic and 90 mmHg diastolic at 2 separate measurements no more than 60 minutes apart during the screening visit); note: patients may be rescreened after adjustment of antihypertensive medicationsXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg) despite medical treatment; patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertension treatmentXx_NEWLINE_xXSubjects must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the average of three BP readings at the time of enrollment is =< 140/90 mmHgXx_NEWLINE_xXPatients must have blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; initiation or adjustment of BP medication is permitted prior to study entry provided that the BP reading prior to enrollment is no greater than 140/90 mmHgXx_NEWLINE_xXUncontrolled hypertension, defined as systolic BP >140 or diastolic >90 despite therapy.Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatmentXx_NEWLINE_xXNo uncontrolled hypertension (BP >150/100mmHg despite full doses of 1 anti-hypertensive medication).Xx_NEWLINE_xXBaseline arterial blood pressure (BP) >= 140/90 mmHg, despite pharmacologic treatment with antihypertensive agents; if the arterial BP measurements at screening are >= 140/90 mmHg in a patient not on pharmacologic treatment for hypertension (HTN), we will initiate pharmacologic therapy and reassess the parameters after 1 week; at that time, patient will be eligible for enrollment on the study if arterial BP is found < 140/90 mmHg on antihypertensive therapyXx_NEWLINE_xXPatients with uncontrolled hypertension (defined as sustained stage 2 hypertension, i.e., systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg) with or without medical therapyXx_NEWLINE_xXPoorly controlled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 100 mmHg) on three or more readings in the past 12 monthsXx_NEWLINE_xXSevere hypertension (diastolic BP > 100 on medication)Xx_NEWLINE_xXBlood pressure (BP) ?140/90 millimeters of mercury (mmHg) at Screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.Xx_NEWLINE_xXAll patients must also have 3 pre-op blood pressures (BP) to average for determining individual perioperative BP goal; it is preferred to utilize office visit BP's to reduce \whitecoat\ effect seen the morning of surgeryXx_NEWLINE_xXPatients with a history of hypertension should be well controlled (blood pressure [BP] =< 140/90) on a regimen of antihypertensive therapyXx_NEWLINE_xXSubjects with congestive heart failure are not eligible, nor are subjects with myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack (TIA) within the past 12 months, uncontrolled hypertension (systolic blood pressure [BP] > 160 or diastolic BP > 90), uncontrolled or symptomatic arrhythmia, or grade 2 or greater peripheral vascular diseaseXx_NEWLINE_xXUncontrolled hypertension, i.e., blood pressure (BP) of >= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; orXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg or diastolic BP > 100 mmHg), or as determined by the investigator during screening.Xx_NEWLINE_xXSystolic/diastolic blood pressure (BP) greater than or equal to 160/100, or below 90/50 (one re-screen allowed)Xx_NEWLINE_xXHypertensive-level readings over three weeks, with at least two of three elevated blood pressure (BP) readings (systolic >= 140 and/or diastolic >= 90); OR one hypertensive crisis reading (systolic >= 165 and/or diastolic >= 100) (eligible for the study without having to return for second or third readings) OR have a known diagnosis of hypertension and have elevated values at one reading (eligible for the study without having to return for second or third readings)Xx_NEWLINE_xXUncontrolled high blood pressure (BP) >= 160/100; persons can be re-screened after controlledXx_NEWLINE_xXSevere hypertension (diastolic BP > 100 on medication)Xx_NEWLINE_xXFever of > 101 degrees Fahrenheit (F) or blood pressure (BP) > 180/95Xx_NEWLINE_xXActive cardiac disease including any of the following:\r\n* Severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association)\r\n* Unstable angina\r\n* Severe arrhythmia (i.e. ventricular tachycardia, flutter fibrillation; ventricular premature complexes occurring close to the preceding T-wave, multifocal complexes)\r\n* Myocardial infarction within 1 year prior to the date of proposed Definity administration\r\n* Uncontrolled systemic hypertension (systolic blood pressure [BP] > 150 mmHg and/or diastolic BP > 90 mmHg despite optimal medical management)Xx_NEWLINE_xXPatient must not have poorly controlled hypertension (defined as systolic blood pressure [SBP] of >= 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg)\r\n* Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; BP must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be < 140/90 mmHg in order for a subject to be eligible for the study prior to study enrollment)Xx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] >= 160 mmHg or diastolic BP >= 95 mmHg)Xx_NEWLINE_xXAdequately controlled blood pressure with or without antihypertensive medications defined as blood pressure (BP) < 150/90 mmHg at screeningXx_NEWLINE_xXUncontrolled hypertension, blood pressure (BP) > 150/100 mmHg; patients with elevated BP may enroll once BP is correctedXx_NEWLINE_xXUncontrolled hypertension (systolic blood pressure [BP] > 150 millimeters of mercury [mmHg] and/or diastolic BP > 100 mmHg), unstable angina, congestive heart failure (CHF) of any New York Heart Association (NYHA) classification (Class II or greater), serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months of enrollmentXx_NEWLINE_xXAdequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ?150/90 mmHg at Screening and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.Xx_NEWLINE_xX